DUBLIN--(BUSINESS WIRE)--May 14, 2018--The "Drug Overview: Dulera" report has been added to ResearchAndMarkets.com's offering.

Dulera ([mometasone + formoterol]; Merck & Co) is an oral inhalation drug that contains a combination of mometasone (an inhaled corticosteroid) and formoterol (a long-acting beta 2 agonist). Mometasone is a glucocorticoid receptor agonist with potent anti-inflammatory activity. Formoterol fumarate is a beta-2 adrenergic receptor agonist and acts as a bronchodilator. Dulera is approved in the US where it is indicated for the treatment of asthma in adults and adolescents aged 12 years and above.

Key Topics Covered:

Product Profiles

Dulera: Asthma

List of Figures

Figure 1: Dulera for asthma - SWOT analysis

Figure 2: Drug assessment summary of Dulera in asthma

Figure 3: Drug assessment summary of Dulera in asthma

Figure 4: Dulera sales for asthma in the US, 2017-26

List of Tables

Table 1: Dulera drug profile

Table 2: Dulera pivotal trial data in asthma

Table 3: Dulera Phase IV trial in asthma

Table 4: Dulera sales for asthma in the US ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/2flrv3/dulera?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006212/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Asthma Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 02:41 PM/DISC: 05/14/2018 02:41 PM

http://www.businesswire.com/news/home/20180514006212/en